Cited by 1,149Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismTrace Elements in Health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., Marsden, C. D.·1989·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.1989.tb07264.x

Open this paper in CoChat — free account

Abstract

Levels of iron, copper, zinc, manganese, and lead were measured by inductively coupled plasma spectroscopy in parkinsonian and age-matched control brain tissue. There was 31-35% increase in the total iron content of the parkinsonian substantia nigra when compared to control tissue. In contrast, in the globus pallidus total iron levels were decreased by 29% in Parkinson's disease. There was no change in the total iron levels in any other region of the parkinsonian brain. Total copper levels were reduced by 34-45% in the substantia nigra in Parkinson's disease; no difference was found in the other brain areas examined. Zinc levels were increased in substantia nigra in Parkinson's disease by 50-54%, and the zinc content of the caudate nucleus and lateral putamen was also raised by 18-35%. Levels of manganese and lead were unchanged in all areas of the parkinsonian brain studied when compared to control brains, except for a small decrease (20%) in manganese content of the medial putamen. Increased levels of total iron in the substantia nigra may cause the excessive formation of toxic oxygen radicals, leading to dopamine cell death.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.1989.tb07264.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease
Dexter, D. T., Carter, C. J., Wells, F. R., Javoy-Agid, F., Agid, Y., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09133.x · Cited by 1,397
Self-citation
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
FERRITIN: STRUCTURE, GENE REGULATION, AND CELLULAR FUNCTION IN ANIMALS, PLANTS, AND MICROORGANISMS
Theil, E. C. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.001445 · Cited by 1,337
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Self-citation
Autoxidation versus Covalent Binding of Quinones as the Mechanism of Toxicity of Dopamine, 6-Hydroxydopamine, and Related Compounds toward C1300 Neuroblastoma Cells in Vitro
Graham, D. G., Tiffany, S. M., BELL, W. R., & Gutknecht, W. F. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13536-0 · Cited by 953
The importance of free radicals and catalytic metal ions in human diseases.
Halliwell, B., & Gutteridge, J. M. C. (1985) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(85)90001-9 · Cited by 941
Iron-Responsive Elements: Regulatory RNA Sequences That Control mRNA Levels and Translation
Casey, J. L., Hentze, M. W., Koeller, D. M., Caughman, S. W., Rouault, T. A., Klausner, R. D., & Harford, J. B. (1988) · Science · doi:10.1126/science.2452485 · Cited by 709
Brain Peroxidase and Catalase in Parkinson Disease
Ambani, L. M., Woert, M. H. V., & Murphy, S. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490440064010 · Cited by 404

Show all 29 references

Research works printed but not linked: 4

Barbeau A., 1985, Uneven prevalence of Parkinson's disease in the province of Quebec, Can. J. Neurol. Sci., 12, 169
Barbeau A., 1986, Advances in Neurology, 299
Donaldson J., 1974, Advances in Neurology, 245
Youdim M. B. H., 1985, Handbook of Neurochemisiry, 731

Sorted by citations

Reactive Oxygen Species and the Central Nervous System
Halliwell, B. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10990.x · Cited by 2,947
Free radicals, antioxidants, and human disease: where are we now?
Halliwell, B. B., Gutteridge, J. M. C., & Cross, C. E. (1992) · PubMed · Cited by 2,156
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
Self-citation
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Role of GPX4 in ferroptosis and its pharmacological implication
Seibt, T. M., Proneth, B., & Conrad, M. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.014 · Cited by 1,520
Role of Free Radicals in the Neurodegenerative Diseases: Therapeutic Implications for Antioxidant Treatment
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
ETIOLOGY AND PATHOGENESIS OF PARKINSON'S DISEASE
Olanow, C. W., & Tatton, W. G. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.123 · Cited by 1,409
The role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn983 · Cited by 1,319
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease
Blum, D. L., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A., Sadoul, R., & Verna, J. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,269
Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105343200 · Cited by 1,103
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Prigent, A., Ruberg, M., Hirsch, É. C., & Agid, Y. (1997) · PubMed · Cited by 1,045
Self-citation
Molecular mechanisms of quinone cytotoxicity
O'Brien, P. J. (1991) · Chemico-Biological Interactions · doi:10.1016/0009-2797(91)90029-7 · Cited by 1,031
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A. K., Simcox, E. M., & Turnbull, D. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 1,013
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Biomarkers of free radical damage
de Zwart, L. L., Meerman, J. H. N., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00196-8 · Cited by 854
Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease
Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778
α-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J., & Uversky, V. N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 683
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons
Zhang, J., Perry, G. L., Smith, M. A., Robertson, D., Olson, S. J., Graham, D. G., & Montine, T. J. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65396-5 · Cited by 639
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 612
Nitric oxide synthase and neuronal vulnerability in parkinson's disease
Hunot, S., Boissière, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., & Hirsch, E. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00578-1 · Cited by 595
Self-citation
Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 594
Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.
Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T., & Gitlin, J. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2539 · Cited by 558
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney‐Sanchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 572
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease
Jenner, P. G., Dexter, D. T., Sian, J., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 545
Self-citation
Zinc Metabolism in the Brain: Relevance to Human Neurodegenerative Disorders
Cuajungco, M. P., & Lees, G. J. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0163 · Cited by 544
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 540
Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis
Hirsch, E. C., Brandel, J. ‐., Galle, P., Javoy‐Agid, F., & Agid, Y. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb08170.x · Cited by 537
Self-citation
Parkinson's disease: pathophysiology
Agid, Y. (1991) · The Lancet · doi:10.1016/0140-6736(91)92989-f · Cited by 530
Self-citation
The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Mini Review
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Neurodegenerative Diseases: An Overview of Environmental Risk Factors
Brown, R. C., Lockwood, A. H., & Sonawane, B. R. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7567 · Cited by 538
Metabolism and functions of copper in brain
Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.01.002 · Cited by 524
Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
Hald, A., & Lotharius, J. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.013 · Cited by 510
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I. B., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 517
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A., & Moreau, C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 494
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P. F., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Lipid Oxidation and Peroxidation in CNS Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities
Adibhatla, R. M., & Hatcher, J. F. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2668 · Cited by 480
Occupational exposures to metals as risk factors for Parkinson's disease
Gorell, J. M., Johnson, C. C., Rybicki, B. A., Peterson, E. L., Kortsha, G. X., Brown, G. G., & Richardson, R. J. (1997) · Neurology · doi:10.1212/wnl.48.3.650 · Cited by 479
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 487
Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease
Jicha, G. A., Berenfeld, B., & Davies, P. J. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990315)55:6 · Cited by 119
Oxidants and the central nervous system: some fundamental questions. Is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?
Halliwell, B. B. (1989) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1989.tb01779.x · Cited by 468
Glutathione peroxidase, glial cells and Parkinson's disease
Damier, P., Hirsch, É. C., Zhang, P., Agid, Y., & Javoy-Agid, F. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90175-f · Cited by 466
Self-citation
The pathogenesis of cell death in Parkinson's disease
Jenner, P. G., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 451
Self-citation
Selenium and selenoproteins in the brain and brain diseases
Chen, J., & Berry, M. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01854.x · Cited by 446
Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases
Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445
Toward in vivo histology: a comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength
Deistung, A., Schäfer, A., Schweser, F., Biedermann, U., Turner, R., & Reichenbach, J. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.055 · Cited by 442
A delicate balance: Iron metabolism and diseases of the brain
Hare, D. J., Ayton, S., Bush, A. I., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 459
Glutathione metabolism and Parkinson's disease
Smeyne, M., & Smeyne, R. J. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.001 · Cited by 436
Oxidative stress and regulated cell death in Parkinson’s disease
Dionísio, P. A., Amaral, J. D., & Rodrigues, C. M. P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101263 · Cited by 443
Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study
Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research · doi:10.1016/0006-8993(92)91334-b · Cited by 427
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Reichert, C. O., de Freitas, F. A., Sampaio‐Silva, J., Rokita-Rosa, L., Barros, P. D. L., Levy, D., & Bydlowski, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228765 · Cited by 431
Untitled work
(1999) · PubMed · Cited by 425
The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy
Gaeta, A., & Hider, R. C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706416 · Cited by 411
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study
Dexter, D. T., Holley, A. E., Flitter, W. D., Slater, T. F., Wells, F. R., Daniel, S. E., Lees, A. J., Jenner, P. G., & MARSDEN, C. D. (1994) · Movement Disorders · doi:10.1002/mds.870090115 · Cited by 407
Self-citation
Iron, Neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401
Glutathione, iron and Parkinson’s disease
Bharath, S., Hsu, M., Kaur, D., Rajagopalan, S., & Andersen, J. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01174-7 · Cited by 394
Plasma Urate and Risk of Parkinson's Disease
Weisskopf, M. G., O’Reilly, É. J., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 395
Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease
Mosley, R. L., Benner, E. J., Kadiu, I., Thomas, M., Boska, M. D., Hasan, K. M., Laurie, C. D., & Gendelman, H. E. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.006 · Cited by 393
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
Martín‐Bastida, A., Ward, R. J., Newbould, R. D., Piccini, P. P., Sharp, D. J., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 393
Self-citation
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citation
Bioenergetic and oxidative stress in neurodegenerative diseases
Bowling, A. C., & Beal, M. F. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00055-b · Cited by 364
Brain iron pathways and their relevance to Parkinson's disease
Berg, D., Gerlach, M., Youdim, M. B. H., Double, K. L., Zecca, L., Riederer, P., & Becker, G. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00608.x · Cited by 362
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes
Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 373
The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?
Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 358
Midbrain iron content in early Parkinson disease
Martin, W. R. W., Wieler, M., & Gee, M. (2008) · Neurology · doi:10.1212/01.wnl.0000286384.31050.b5 · Cited by 355
The relevance of iron in the pathogenesis of Parkinson’s disease
Sian‐Hülsmann, J., Mandel, S. A., Youdim, M. B. H., & Riederer, P. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07132.x · Cited by 364
The Relevance of Iron in the Pathogenesis of Parkinson's Disease
Götz, M. E., Double, K. L., Gerlach, M., Youdim, M. B. H., & RIEDERERE, P. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.017 · Cited by 343
T1 and T2 in the Brain of Healthy Subjects, Patients with Parkinson Disease, and Patients with Multiple System Atrophy: Relation to Iron Content
Vymazal, J., Righini, A., Brooks, R. A., Canesi, M., Mariani, C. B., Leonardi, M., & Pezzoli, G. (1999) · Radiology · doi:10.1148/radiology.211.2.r99ma53489 · Cited by 341
Copper: Effects of Deficiency and Overload
Scheiber, I. F., Dringen, R., & Mercer, J. F. B. (2013) · Metal ions in life sciences · doi:10.1007/978-94-007-7500-8_11 · Cited by 349
Ferroptosis and cell death mechanisms in Parkinson's disease
Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 353
Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture
Michel, P. P., & Hefti, F. F. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490260405 · Cited by 339
Oxidative stress and antioxidant therapy in Parkinson's disease
Ebadi, M., Srinivasan, S. K., & Baxi, M. D. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00029-1 · Cited by 337
Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases
Rao, A. V., & Balachandran, B. (2002) · Nutritional Neuroscience · doi:10.1080/1028415021000033767 · Cited by 341
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W. C., Hubble, J. P., Busenbark, K. L., Lilienfeld, D. E., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 350
A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes
Esposito, E., Rotilio, D., DIMATTEO, V., Giulio, C. D., Cacchio, M., & Algeri, S. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00078-7 · Cited by 330
Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla
Ordidge, R. J., Gorell, J. M., Deniau, J. C., Knight, R. A., & Helpern, J. A. (1994) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910320309 · Cited by 318
1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles
Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., & Minakami, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90498-c · Cited by 320
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease
Dexter, D. T., Sian, J., Rose, S., Hindmarsh, J. G., Mann, V. M., Cooper, J. A. D., Wells, F. R., Daniel, S. E., Lees, A. J., Schapira, A. H. V., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410350107 · Cited by 317
Self-citation
Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease
Drechsel, D. A., & Patel, M. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.02.008 · Cited by 314
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
Gu, M., Cooper, J. A. D., Taanman, J., & Schapira, A. H. V. (1998) · Annals of Neurology · doi:10.1002/ana.410440207 · Cited by 313
Vulnerability of the nigrostriatal system as detected by transcranial ultrasound
Berg, D., Becker, G., Zeiler, B., Tucha, O. M., Hofmann, E. P., Preier, M., Benz, P. M., Jost, W. H., Reiners, K., & Lange, K. W. (1999) · Neurology · doi:10.1212/wnl.53.5.1026 · Cited by 312
Integrated Laplacian‐based phase unwrapping and background phase removal for quantitative susceptibility mapping
Li, W., Avram, A., Wu, B. H., Xiao, X., & Liu, C. (2013) · NMR in Biomedicine · doi:10.1002/nbm.3056 · Cited by 311
The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis
Santana-Codina, N., Gikandi, A., & Mancias, J. D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-62026-4_4 · Cited by 329
The possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. F. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301
Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease
Schipper, H. M., Liberman, A., & Stopa, E. G. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6752 · Cited by 299
Iron in Neurodegeneration – Cause or Consequence?
Ndayisaba, A., Kaindlstorfer, C., & Wenning, G. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00180 · Cited by 305
The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons
Ben‐Shachar, D., Eshel, G., Finberg, J. P. M., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb11444.x · Cited by 299
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Beal, M. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_16 · Cited by 298
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
THE ROLE OF VESICULAR TRANSPORT PROTEINS IN SYNAPTIC TRANSMISSION AND NEURAL DEGENERATION
Liu, Y., & Edwards, R. H. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.125 · Cited by 295

Authors: Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D.
Affiliations: King's College London (GB)
National Hospital for Neurology and Neurosurgery (GB)
Inserm (FR)
Corresponding author: Jenner, P.
ORCID: Dexter, D. T.
Jenner, P.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 1989-06
Volume: 52
Issue: 6
Pages: 1830-1836
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.1989.tb07264.x
OpenAlex: W1985613988
Cited by: 1,149
References: 29
Citations by year: 2026: 18 · 2025: 26 · 2024: 31 · 2023: 32 · 2022: 46 · 2021: 42 · 2020: 35 · 2019: 33 · 2018: 35 · 2017: 41 · 2016: 45 · 2015: 21 · 2014: 37 · 2013: 45 · 2012: 41
FWCI: 24.67
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 6335 d)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Nursing › Nutrition and Dietetics › Trace Elements in Health
Keywords: Parkinson's disease, substantia nigra, iron, copper, zinc, manganese, lead, globus pallidus, caudate nucleus, putamen, oxidative stress, neurodegeneration
MeSH terms: Aged, Aged, 80 and over, Brain, Female, Humans, Ions, Iron, Male, Metals, Parkinson Disease, Substantia Nigra, Tissue Distribution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks